Skip to content
The Nexus
DossierENTITY

Vyvgart

Coverage of Vyvgart in the Nexus archive.

Earliest in view: Jul 27 · 07:26 UTCMost recent: Aug 17 · 08:03 UTC
Co-mentioned in this coverage
Argenx SEorganization1autoimmune drugtopic1Europeanplace1Biotechtopic1Argenxorganization1Forte Biosciencesorganization1Dallasplace1Belgiumplace1
Recent coverage
  • BUSINESSAug 17 · 08:03 UTCBLOOMBERG
    Argenx Soars on Latest Trial Success for Autoimmune Drug Vyvgart

    Argenx SE's shares jumped after the European biotech reported a successful trial for its drug Vyvgart. The company reported that this was the latest large, successful trial conducted for the autoimmune drug.

  • BUSINESSJul 27 · 07:26 UTCSTAT NEWS
    STAT+: Argenx to buy Forte Biosciences for $2.2B

    Argenx agreed to acquire Forte Biosciences for $2.2 billion in cash, valuing the Dallas-based company at $77 per share, a 41% premium. The deal aims to expand Argenx's immunology pipeline, leveraging its success with the autoimmune drug Vyvgart.